CHRNChronoScale Corporation
Price
+320%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market undecided.
Founded in 2005, we are a Nevada corporation that designs, develops, and markets exoskeleton products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The majority of our sales are generated from our Enterprise Health products, which includes the sales of products and services related to neurorehabilitation in clinical settings.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ChronoScale Corporation (CHRN) reported revenue of $2.1M in Q3 2026 (quarter ended Mar 31, 2026), down 37% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $6.9M. For the full year FY2026, revenue was $72M (+299% year on year) and net income −$50M. Its largest region in Q1 2026 was United States at $1.5M, 87% of the disclosed total, well ahead of France at 12%.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 6, 2026Davis As previously announced, on September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”)Director or officer change · Form 8-K
- Oct 2, 2026Separation and Severance Agreement with Mr. Jones On September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”) (the “Transaction”)Director or officer change · Form 8-K
- Sep 16, 2026Effective as of September 12, 2026, ChronoScale Intermediate, LLC, a Nevada limited liability company (f/k/a Ekso Bionics Holdings, Inc. and ChronoScale Corporation, the “Borrower”) and Ekso Bionics, Inc., a Delaware corporation (the “Guarantor” and, together with the Borrower, the “Loan Parties”) entered into the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2026 · $1.8MThe company’s own SEC segment disclosure.
- United States$1.5M87%
- France$207.0K12%
- Italy$26.0K1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Information Technology Services
Ranks #29 of 31 by RyuScore